MRC1 and colorectal carcinoma: Currently, MMR defects’ identification in CRC and has a role beyond LS identification—selection of stage II patients for chemotherapy (CT), choice of the type of adjuvant CT and selection of stage IV patients for immunotherapy all depend on MSI status.